INTRODUCTION
Humanized or chimeric monoclonal antibodies directed against the interleukin-2 (IL-2) receptor ␣-chain (CD25) are widely used in clinical transplantation to prevent acute allograft rejection [1] [2] [3] . The mechanism of action of these antibodies is mediated primarily by inhibition of IL-2 binding to CD25. The epitope recognized by these antibodies has recently been identified [4] and overlaps with the previously characterized site of CD25 interaction with IL-2. It has been demonstrated that they inhibit early IL-2R signal transduction events [5] and blocks T-cell activation and expansion in vitro [6 -8] . Their effects on T lymphocytes have been widely studied; however, their impact on human monocyte-derived dendritic cells (DC) has never been reported.
Dendritic cells play a key role in the initiation and regulation of both adaptive and innate immune responses [9 -16] . DC progenitors leave the bone marrow and differentiate into circulating precursors that differentiate into immature DC distributed throughout the peripheral tissues and mucosa [13, 15] . They are characterized by a high capacity for antigen uptake and processing [13] . In response to inflammatory stimuli, immature DC rapidly undergo complete genetic reprogramming necessary to progress to mature cells characterized by a high capacity for antigen presentation and T cell priming [16 -18] . The mature DC then migrate to the secondary lymphoid organs where they interact with T cells. This complex "maturation" process involves not only the up-regulation of costimulatory surface proteins and the optimization of antigen presentation capacities, but also the production of cytokines and chemokines [15, 18] that profoundly influence the outcome of the T-cell response. The signals delivered by DC are believed to direct the T-cell immune response toward either Th1 or Th2 profile [19 -22] . However, the early decision-making mechanisms that determine these cytokine synthesis patterns have still not been fully defined. It has recently been demonstrated that mouse and human DC can produce IL-2 after activation with several stimuli [23] . Furthermore, DC from IL-2Ϫ/Ϫ mice are impaired in their ability to induce allogeneic CD4 T-cell proliferation [18] , suggesting that IL-2 confers its T-cell prim-ing capacity on DC. Although this has been attributed to a deficit in IL-2 activity on T cells, it is possible that DC from IL-2Ϫ/Ϫ mice present a defect in DC function that might contribute to the T-cell unresponsiveness. The effects of anti-CD25 on human DC have not been investigated, and only a few authors have investigated the role of the IL-2 pathway in DC functions [24 -26] . We, therefore, decided to investigate whether antagonizing IL-2 signaling with humanized anti-CD25 antibodies could affect human DC functions.
In this study, we confirmed that stimulation of human monocyte-derived DC with LPS strongly up-regulated CD25 expression, as previously reported [25, 27] . We then demonstrated that adding humanized anti-CD25 monoclonal antibodies to LPS induced a decrease in IL-12, IL-6, IL1␤, TNF-␣, and IFN-␥ production, and an increase in IL-10 synthesis by human DC compared with stimulation with LPS alone. Furthermore, we showed that these modifications affected the T-helper priming ability of DC and polarized the alloimmune response toward TH2. In contrast, humanized anti-CD25 monoclonal antibodies did not affect the up-regulation of CD86, CD80, CD83, HLADR, or CD40 induced by LPS, suggesting that the IL-2 pathway was not involved in this process.
In summary, this study reports some previously unrecognized properties of humanized anti-CD25 monoclonal antibodies on DC functions that may contribute to their therapeutic action in several immunological disorders such as autoimmune diseases [28 -30] and acute human allograft rejection [1] . Furthermore, this study also shed some light on the role of IL-2 in human DC activation.
MATERIALS AND METHODS

Antibodies and reagents
Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) from Abcys SA, (Paris, France), and recombinant human IL-4 (rhIL-4) from R&D Systems (Abington, UK) were used for DC generation. IL-2 was purchased from R&D Systems; lipopolysaccharide (LPS; Escherichia coli), used at 50 ng/ml was obtained from Sigma Aldrich Chemical (St. Quentin Fallavier, France).
Monoclonal antibodies daclizumab (Zenapax; Roche Pharmaceuticals, Neuilly sur Seine, France) and basiliximab (Simulect Novartis Rueil-Malmaison, France), humanized and chimeric monoclonal antibodies directed against human CD25, were used in cell cultures at 100 g/ml unless otherwise indicated. Trastuzumab, a humanized monoclonal antibody against the extracellular domain of HER-2 (herceptin; Roche Pharmaceuticals) was used as a negative control antibody at 100 g/ml. ELISA assays for IL-1␤, IL-5, IL-6, IL-12, IL-10, TNF-␣, and IFN-␥ were carried out with kits purchased from eBioscience (Montrouge, France). Anti-IL-2 antibody was purchased from e-Bioscience (Montrouge, France), and HRP-conjugated anti rabbit Ig(H ϩ L) was obtained from Cell Signaling Technology (Danvers, MA).
For flow cytometry analysis, phycoerythrin (PE)-conjugated anti-CD83, PEconjugated anti-CD80, PE-conjugated anti-CD86, PE-conjugated anti-CD40, PE-conjugated anti-HLA-DR, and their respective isotype controls were obtained from Immunotech, (Marseille, France). FITC-conjugated anti-CD122 and anti-CD132 (␤ and ␥ chain of the IL-2 receptor, respectively) were purchased from Beckman-Coulter (Villepinte, France) and PE-conjugated mouse isotype controls were from Becton Dickinson (Grenoble, France).
The complete medium for cell cultures consisted of RPMI 1640, (GIBCO, Cergy-Pontoise France), 2 mM L-glutamine, 50 U/ml penicillin, 50 g/ml streptomycin, and 10% heat-inactivated fetal calf serum (FCS, GIBCO, CergyPontoise, France).
Generation of dendritic cells from peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were obtained by cytapheresis from healthy volunteers following informed written consent. PBMCs were isolated by Ficoll Hypaque density gradient centrifugation (density 1.077, Lymphoprep; Abcys) and resuspended in culture medium after 2 washings. Monocyte-derived dendritic cells were prepared either after selective adhesion of monocytes to plastic as described previously [31] or by negative selection using magnetic beads from Dynal (Dynabeads Mypure Monocyte kit 2). Briefly, PBMC were incubated for 45 min at 37°C in 5% CO 2 in culture flasks (100 million in a 75 cm 2 -Falcon flask, Becton Dickinson, Mountain View, CA), and nonadherent cells were discarded and medium containing rh GM-CSF (1000 IU/ml) and rhIL4 (25 ng/ml) was added. When specified, monocytes were obtained from PBMC by negative selection with magnetic beads coupled with a combination of monoclonal antibodies specific for CD19, CD3, CD7, CD16, CD56, CDw123, and CD235a, according to the manufacturer's instructions (Dynabeads Mypure Monocyte kit 2). Cells were then resuspended in culture medium (containing 1000 IU/ml rh GM-CSF and 25 ng/ml rh IL-4). At the end of 5 days' culture, cells (obtained after either adhesion or negative selection on beads) were harvested, washed, and replated in 24-well plates (Falcon, Becton Dickinson, Mountain View, CA) at a density of 2 ϫ 10 6 cells/well in 2 ml of culture medium containing rhGM-CSF (1000 IU/ml) and rhIL4 (25 ng/ml). Maturation was induced by adding LPS (50 ng/ml) for the last 48 h of culture. In addition, we added IL-2 (100 IU/ml) or anti-CD25 monoclonal antibodies (100 g/ml, either daclizumab or basiliximab when mentioned) or trastuzumab as negative control antibodies (100 g/ml), during this maturation period when mentioned, the latter being used as a negative control antibody. Finally, on day 7, DC were harvested, washed twice in RPMI, and used for further experiments. The purity of DC cultures, as assessed by FACS analysis, was routinely above 96% and 99% after adhesion or magnetic bead selection, respectively. 
Flow cytometry analysis
Purification of CD4 T cells and mixed lymphocyte reaction
Allogeneic CD4
ϩ T cells of subjects unrelated to the DC donors were purified from PBMC by positive selection with magnetic beads coated with an anti-CD4 antibody (Dynabeads, Dynal, Compiègne France), according to the manufacturer's instructions. Cell purity was routinely above 95%. Mixed lymphocyte reactions were carried out as follows: dendritic cells were washed twice, resuspended in complete medium, and then mixed with purified allogeneic CD4 ϩ T cells in 96-well flat-bottomed plates in triplicate, at a ratio of 10 
Enzyme-linked immunosorbent assays
Cell culture supernatants were harvested and stored at -80°C until assayed for the cytokines. Human IL-10, IFN-␥, IL-6, IL-1␤, IL-12p70 TNF-␣, and IL-5 concentrations were measured by enzyme-linked immunosorbent assays (ELISAs) using Ready-Set-Go kits from E-Bioscience (Montrouge, France), according to the manufacturer's instructions. Briefly, microtiter plates were coated overnight at 4°C with antibodies specific for IL-10, IFN-␥, IL-6, IL-1␤, IL-12p70 TNF-␣, and IL-5, from e.Bioscience (Montrouge, France). The plates were washed and blocked according to the manufacturer's instructions. Samples and standards were analyzed in triplicate and assayed with the avidinperoxidase system. Optical densities were measured in an ELISA plate-reader at 450-nm wavelength
RESULTS
Stimulation of DC with LPS-induced CD25 expression in human monocyte-derived DC
We evaluated IL-2 receptor ␣ chain (CD25) expression on immature and LPS-matured DC. As shown in Fig. 1, CD25 was virtually absent on the surface of immature DC (Fig. 1A) . In contrast, up to 93% of LPS-matured DC (Fig. 1B) expressed CD25 (expression slightly varied from 80 to 95% between donors). We also observed that this induction of CD25 was sensitive to inhibition by cyclosporine A (data not shown). Interestingly, TNF-␣ at 20 ng/ml also induced expression of CD25 on DC, although at a lower level (only 10 to 50% of DC became CD25-positive, data not shown). We also analyzed the expression of the ␤ and ␥ chains (Fig. 1, A and B ) of IL-2R (CD122 and CD132, respectively) on human DC. We found that DC expressed these markers; however, expression was up-regulated after the maturation signal, as shown in Fig. 1, A and B. Taken together, these findings suggest that mature human DC express a functional IL-2 receptor. We also investigated the time point at which CD25 was induced, and FACS (Fig. 1C) . Interestingly, CD25 appeared after CD83 up-regulation (Fig. 1C) . These results prompted us to investigate how IL-2 signaling in DC affected their maturation process and their cytokine synthesis pattern upon LPS stimulation.
Humanized anti-CD25 antibodies do not impair the LPS-induced up-regulation of maturation markers on the surface of DC
The complex "maturation" process triggered in DC by inflammatory stimuli is associated with the up-regulation of several surface markers, such as costimulatory proteins (CD80, CD86, CD40) and molecules involved in antigen presentation such as HLA DR. To explore the role of IL-2 in this process further, we analyzed the effects of anti-CD25 antibodies on the cell surface expression of these maturation markers induced by LPS. Monocyte-derived immature DC were stimulated with LPS in the presence or absence of daclizumab, and cell surface expression of CD83, CD80, CD86, CD40, and HLADR was analyzed by FACS . Figure 2 shows that the level of expression of these maturation markers was comparable in both conditions. Similar results were obtained with basiliximab (data not shown). These results suggested that IL-2 did not play any significant role in the LPS-induced up-regulation of maturation markers on DC. In addition, our results showed that adding IL-2 (100 U/ml) to immature DC cultures affected neither cell surface marker expression (of CD83 and CD25) nor IL-12 and IFN-␥ synthesis (data not shown). These results suggested that IL-2 did not induce any maturation signal in immature DC, in accordance with the absence of CD25 expression on immature DC.
Antagonizing IL-2R in LPS-matured DC down-regulates ␥-interferon, IL-12, and proinflammatory cytokines but up-regulates IL-10 synthesis
The cytokine synthesis profile of DC plays an important role in orientating the innate and adaptive immune response: IFN-␥, IL-12, and IL-10 are three important cytokines known to bias the immune response. We, therefore, decided to explore the synthesis of these cytokines by DC after the addition of blocking anti-CD25 antibody (100 g/ml). We also analyzed the production of proinflammatory cytokines such as IL-1␤, IL-6, and TNF-␣.
One million monocyte-derived DC were matured with LPS alone (LPS-DC) or with LPS and daclizumab (LPSDCϩaCD25) or LPS and IL-2 (LPS-DCϩIL-2), and cytokine synthesis was analyzed by ELISA in the supernatants of these cultures. Analysis showed that the levels of cytokine production by LPS-activated DC were highly variable between donors. The mean values of cytokine concentrations and standard deviations and medians were 60 Ϯ 20 pg/ml, median 59 pg/ml for IFN-␥; 124 Ϯ 118 pg/ml, median 53 pg/ml for IL-12; 868 Ϯ 364 pg/ml, median 625 pg/ml for IL-1; 6059 Ϯ 3680 pg/ml, median 6830 pg/ml for IL-6; 705 Ϯ 200 pg/ml, median 720 pg/ml for IL-10; and 220 Ϯ 135 pg/ml, 170 pg/ml for TNF-␣. Because of this high variability between donors, we chose to normalize the units for each donor. Figure 3 shows that blocking anti-CD25 antibody constantly decreased IFN-␥, IL-12, IL-1, IL-6, and TNF-␣ synthesis by DC after LPS stimulation (Fig. 3A) and up-regulated IL-10 production (Fig. 3A, top right) . Wilcoxon tests demonstrated that all modifications induced by anti-CD25 antibodies were statistically significant for all cytokines (PϽ0.031). Similar results were obtained with basiliximab, another anti-CD25-blocking monoclonal antibody (data not shown). On the other hand, we showed that exogeneous IL-2 had opposite effects (Fig. 3B) , increasing both IFN-␥ and IL-12 production and slightly reducing IL-10 synthesis. In addition, as shown in Fig. 3C , we demonstrated that the inhibition of IFN-␥ production by daclizumab was dose dependent. To clearly demonstrate that IFN-␥ was synthesized by DC rather than by contaminating cells, we analyzed intracytoplasmic IFN-␥ staining by FACS in highly purified DC cultures obtained after negative selection of monocytes with magnetic beads. As shown in Fig. 4A , DC-SIGN (CD209) and CD1a-expressing Figure 4B shows that these highly purified LPS-activated DC stained positive for intracytoplasmic IFN-␥ (Fig. 4B, black line) and that anti-CD25 decreased the mean fluorescence intensity (MFI) of IFN-␥ intracytoplasmic staining (Fig. 4B, gray line) . In addition, ELISA analysis of supernatants of these cultures showed that anti-CD25 inhibited IFN-␥ production (Fig. 4C) . Taken together, these findings showed that anti-CD25 monoclonal antibodies decreased IFN-␥ synthesis by human DC.
IL-2 affects the ability of mature DC to stimulate allogeneic CD4
ϩ T cells
Since we demonstrated that anti-CD25 antibodies strongly influenced the cytokine synthesis patterns of DC, we then investigated to better determine how IL-2 might influence the ability of DC to prime allogeneic T cells. For this purpose, CD4 ϩ T cells were incubated for 5 days with allogeneic DC previously pretreated with LPS either alone (LPS-DC) or with anti-CD25-antibody (LPSϩaCD25-DC in Fig. 5A ) or with IL-2 (LPSϩIL-2-DC in Fig. 5B ). Proliferation was analyzed by measuring incorporation of 3 H-thymidine. As shown in Fig. 5A , anti-CD25 pretreatment reduced the ability of LPS-DC to induce allogeneic CD4 ϩ T-cell proliferation compared with LPS-matured DC (Pϭ0.0001 Wilcoxon test with the results of eight experiments), and IL-2 had opposite effects (Fig. 5B) . This result suggested that IL-2 signaling was important to confer its T-cell priming ability on DC.
Then, in order to investigate how anti-CD25 might influence the ability of DC to prime TH1 or TH2 allogeneic T cells, we compared IL-5 concentrations in allogeneic MLR supernatants using DC matured with either LPS alone or LPS with anti-CD25 as APC stimulators. We found that IL-5 synthesis was higher when using DC pretreated with anti CD25 (Fig. 5C) . These results suggested that IL-2 played a significant role in conferring on DC their ability to orientate the immune response toward TH1. 
DISCUSSION
Humanized or chimeric monoclonal antibodies directed against CD25 are widely used in clinical transplantation to prevent acute allograft rejection [1] [2] [3] . These antibodies inhibit the binding of IL-2 to CD25 and block T-cell activation and expansion in vitro [6 -8] . Although their effects on T lymphocytes have been extensively studied, their impact on human monocyte-derived DC has never previously been reported. In addressing this question, we found that CD25 was not detectable on immature monocyte-derived DC and that a maturation signal such as TLR4 ligand (LPS) induced strong and stable expression of CD25. This confirmed the results of other studies obtained with monocyte derived DC and plasmacytoid DC [25, 27] . The up-regulation of surface markers (such as CD80, CD86, HLADR, CD40) during the DC maturation process plays an important role in the acquisition of T-cell activation ability by DC, but the signals involved in this process have not been clearly delineated. Our study shows that blocking CD25 simultaneously with maturation signals did not impair the up-regulation of these surface markers. This suggests that IL-2 is probably not involved in this process. This is in line with the results reported by Granucci et al. in a mouse model, showing that surface expression of maturation markers on wild-type and IL-2Ϫ/Ϫ DCs were equally induced on both types of cell by bacterial stimulation [18] .
We then showed that anti-CD25 antibodies increased IL-10 production and decreased IL-12 IFN-␥ and proinflammatory cytokine (IL-1␤, TNF-␣, and IL-6) synthesis by DC upon LPS stimulation and that exogeneous IL-2 had opposite effects on IL-10, IL-12, and IFN-␥ production. This suggested that IL-2 signaling played an important role in regulating the cytokine synthesis pattern of DC. The role of the IL-2 pathway in DC has rarely been investigated and remains a matter of debate. In mice, Kronin et al. [24] found no expression of the IL-2R␤ chain on DC in culture and suggested that the induction of CD25 on DC was a "developmental accident." In contrast, we found constitutive expression of the ␤ chain of IL-2R in human DC, in accordance with other studies in humans [32, 33] . Taken together, these findings demonstrate that IL-2R is able to deliver a signal to DC. However, the direct effects of IL-2 signaling in DC deserve further analysis, particularly to determine whether a high level of IL-10 plays a role in the inhibition of IL-12 synthesis, as suggested by other experimental models with antigen-presenting cells [34, 35] .
Interestingly, our results suggested that IL-2 was produced by the DC themselves, since CD25-blocking antibodies were able to down-regulate IFN-␥ production in highly purified DC cultures (purity of 99%). This was in accordance with results obtained in mice and in humans, as well as showing that DC synthesize IL-2 in response to several inflammatory stimuli [18, 23] .
We then showed that IL-2 affects the ability of mature DC to stimulate allogeneic CD4 ϩ T-cells, suggesting that IL-2 is important for DC to become fully competent to prime allogeneic T cells. Since we demonstrated that anti-CD25 antibodies did not impair the LPS-induced up-regulation of several key costimulatory molecules on DC, the inhibition of the priming ability probably resulted from the modifications of the cytokine synthesis pattern reported in this study (low levels of IL-12 and IFN-␥ and high levels of IL-10). It has previously been shown that IL-10 has an inhibitory function in alloantigen responses [34, 35] . In contrast, IL-12 and IFN-␥ have a well-known ability to activate Th1 cells. Accordingly, the cytokine environment created by anti-CD25-treated DC is not favorable to optimal stimulation of allogeneic Th1 cells. It has been demonstrated that DC play an important role in polarizing the immune response toward Th1 or Th2 type [19, 21] , but the molecular mechanisms involved in such regulation have not yet been fully explained. The results of the present study suggest that high levels of IL-2 signaling in DC might be important to polarize the immune response toward a Th1 response.
Finally, the current study should contribute to better discrimination between several processes in DC and may help to clarify some terminology problems. Previous studies, especially in mice, have reported that the up-regulation of several surface markers on DC, often referred to as the "mature" phenotype, does not necessarily lead to "effector DC " capable of priming T-helper cells [10, 36, 37] , suggesting that other signals are necessary. The results presented in the this study suggest that triggering the IL-2 pathway in DC might be one of these signals. Furthermore, the impact of humanized anti-CD25 antibodies on human DC reported in the present study constitutes a previously unrecognized effect that might contribute to their clinical efficacy in preventing acute allograft rejections.
